Lymecycline


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : PO Susceptible infections 408 mg bid. May increase to 1,224-1,632 mg over 24 hr in severe infections. Acne 408 mg/day continued for at least 8 wk.
Dosage Details
Oral
Susceptible infections
Adult: 408 mg bid. May increase to 1,224-1,632 mg over 24 hr in severe infections.
Child: ≥12 yr Same as adult dose.

Oral
Acne
Adult: 408 mg daily continued for at least 8 wk.
Child: ≥12 yr Same as adult dose.
Administration
Should be taken on an empty stomach. Take 1 hr before or 2 hr after meals.
Contraindications
Hypersensitivity to lymecycline or other tetracyclines. Overt renal insufficiency. Pregnancy and lactation. Concomitant use w/ methoxyflurane or oral retinoids.
Special Precautions
Patient w/ myasthenia gravis. May exacerbate SLE. Hepatic impairment.
Adverse Reactions
Anaphylaxis, angioedema, blood disorders, exfoliative dermatitis, hepatotoxicity, hypersensitivity reactions, pancreatitis, pericarditis, photosensitivity, rash, Stevens-Johnson syndrome, urticaria; antibiotic-associated colitis, benign intracranial HTN, bulging fontanelles, diarrhoea, dysphagia, headache, oesophageal irritation, visual disturbances, vomiting, dental staining, enamel hypoplasia.
Patient Counseling Information
This drug may cause photosensitivity reactions, avoid exposure to direct sunlight and UV light.
MonitoringParameters
Monitor lymecycline serum levels.
Drug Interactions
Decreased absorption w/ Ca, Al, Mg, bismuth and zinc salts, antacids, bismuth containing ulcer-healing drugs, Fe preparations and quinapril. Increased effects of anticoagulants. Decreased plasma levels w/ barbiturates, phenytoin or carbamazepine.
Potentially Fatal: Increased risk of kidney failure w/ methoxyflurane. Increased risk of benign intracranial HTN w/ oral retinoids.
Lab Interference
May cause false-positive urine glucose determinations. May also interfere w/ fluorometric determinations of urine catecholamines resulting in falsely increased values (Hingerty's method).
Action
Description: Lymecycline is a tetracycline derivative which blocks the access of bacterial aminoacyl-tRNA to the mRNA-ribosome complex by binding to the 30S ribosome subunit, preventing the addition of amino acids to the growing peptide chain in protein synthesis.
Pharmacokinetics:
Absorption: Readily absorbed from the GI tract. Time to peak plasma concentration: W/in 3-4 hr.
Distribution: Distributed in most body tissues and fluids, and notably in the lungs, bones, muscles, liver, bladder, prostate, bile and urine. Crosses the placenta and enters breast milk.
Excretion: Mainly via urine and secondarily in the bile. Plasma half-life: Approx 10 hr.
Chemical Structure

Chemical Structure Image
Lymecycline

Source: National Center for Biotechnology Information. PubChem Database. Lymecycline, CID=54707177, https://pubchem.ncbi.nlm.nih.gov/compound/Lymecycline (accessed on Jan. 22, 2020)

Storage
Store below 25°C. Protect from light.
MIMS Class
ATC Classification
J01AA04 - lymecycline ; Belongs to the class of tetracyclines. Used in the systemic treatment of infections.
References
Buckingham R (ed). Lymecycline. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 31/03/2016.

Joint Formulary Committee. Lymecycline. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 31/03/2016.

Disclaimer: This information is independently developed by MIMS based on Lymecycline from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in